APO Research
Talk to an analyst

APO RESEARCH · REPORT

Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

Selected research

Market Outlook & Growth Opportunities

Global Induced Pluripotent Stem Cells (iPSCs) Market Outlook and Growth Opportunities 2026

20 December 2025190 pages

Choose your research edition.

Industry ResearchInduced Pluripotent Stem Cells (iPSCs) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Induced Pluripotent Stem Cells (iPSCs) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Induced Pluripotent Stem Cells (iPSCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Induced Pluripotent Stem Cells (iPSCs) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.

The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.

Read the full market overview

This report provides an overview of the global Induced Pluripotent Stem Cells (iPSCs) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Induced Pluripotent Stem Cells (iPSCs) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Induced Pluripotent Stem Cells (iPSCs) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Induced Pluripotent Stem Cells (iPSCs) market.

Induced Pluripotent Stem Cells (iPSCs) Segment by Company

Fujifilm Holding Corporation (CDI)

Ncardia

Sumitomo Dainippon Pharma

Astellas Pharma Inc

Fate Therapeutics, Inc

Pluricell Biotech

Cell Inspire Biotechnology

ReproCELL

Induced Pluripotent Stem Cells (iPSCs) Segment by Type

Human iPSCs

Mouse iPSCs

Induced Pluripotent Stem Cells (iPSCs) Segment by Application

Academic Research

Drug Development and Discovery

Toxicity Screening

Regenerative Medicine

Others

Induced Pluripotent Stem Cells (iPSCs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Induced Pluripotent Stem Cells (iPSCs) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Induced Pluripotent Stem Cells (iPSCs) key companies, revenue, market share, and recent developments.

3. To split the Induced Pluripotent Stem Cells (iPSCs) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Induced Pluripotent Stem Cells (iPSCs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Induced Pluripotent Stem Cells (iPSCs) significant trends, drivers, influence factors in global and regions.

6. To analyze Induced Pluripotent Stem Cells (iPSCs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Induced Pluripotent Stem Cells (iPSCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Induced Pluripotent Stem Cells (iPSCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Induced Pluripotent Stem Cells (iPSCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Induced Pluripotent Stem Cells (iPSCs) industry.

Chapter 3: Detailed analysis of Induced Pluripotent Stem Cells (iPSCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Induced Pluripotent Stem Cells (iPSCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Induced Pluripotent Stem Cells (iPSCs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Induced Pluripotent Stem Cells (iPSCs) Industry Trends Table 2. Induced Pluripotent Stem Cells (iPSCs) Industry Drivers Table 3. Induced Pluripotent Stem Cells (iPSCs) Industry Opportunities and Challenges Table 4. Induced Pluripotent Stem Cells (iPSCs) Industry Restraints Table 5. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Company (2021-2026) Table 7. Global Induced Pluripotent Stem Cells (iPSCs) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Induced Pluripotent Stem Cells (iPSCs) Key Company Manufacturing Base & Headquarters Table 9. Global Induced Pluripotent Stem Cells (iPSCs) Company, Product Type & Application Table 10. Global Induced Pluripotent Stem Cells (iPSCs) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Induced Pluripotent Stem Cells (iPSCs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Human iPSCs Table 15. Significant Companies of Mouse iPSCs Table 16. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type (2021-2026) Table 20. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Academic Research Table 22. Significant Companies of Drug Development and Discovery Table 23. Significant Companies of Toxicity Screening Table 24. Significant Companies of Regenerative Medicine Table 25. Significant Companies of Others Table 26. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application (2021-2026) Table 30. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application (2027-2032) Table 31. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Region (2021-2026) Table 34. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Region (2027-2032) Table 36. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Market Share by Country (2021-2026) Table 39. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Market Share by Country (2027-2032) Table 41. Fujifilm Holding Corporation (CDI) Company Information Table 42. Fujifilm Holding Corporation (CDI) Business Overview Table 43. Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 45. Fujifilm Holding Corporation (CDI) Recent Development Table 46. Ncardia Company Information Table 47. Ncardia Business Overview Table 48. Ncardia Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Ncardia Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 50. Ncardia Recent Development Table 51. Sumitomo Dainippon Pharma Company Information Table 52. Sumitomo Dainippon Pharma Business Overview Table 53. Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 55. Sumitomo Dainippon Pharma Recent Development Table 56. Astellas Pharma Inc Company Information Table 57. Astellas Pharma Inc Business Overview Table 58. Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 60. Astellas Pharma Inc Recent Development Table 61. Fate Therapeutics, Inc Company Information Table 62. Fate Therapeutics, Inc Business Overview Table 63. Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 65. Fate Therapeutics, Inc Recent Development Table 66. Pluricell Biotech Company Information Table 67. Pluricell Biotech Business Overview Table 68. Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 70. Pluricell Biotech Recent Development Table 71. Cell Inspire Biotechnology Company Information Table 72. Cell Inspire Biotechnology Business Overview Table 73. Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 75. Cell Inspire Biotechnology Recent Development Table 76. ReproCELL Company Information Table 77. ReproCELL Business Overview Table 78. ReproCELL Induced Pluripotent Stem Cells (iPSCs) Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. ReproCELL Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 80. ReproCELL Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Induced Pluripotent Stem Cells (iPSCs) Product Image Figure 2. Global Induced Pluripotent Stem Cells (iPSCs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Induced Pluripotent Stem Cells (iPSCs) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Human iPSCs Image Figure 8. Mouse iPSCs Image Figure 9. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type (2021-2032) Figure 12. Academic Research Image Figure 13. Drug Development and Discovery Image Figure 14. Toxicity Screening Image Figure 15. Regenerative Medicine Image Figure 16. Others Image Figure 17. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application (2021-2032) Figure 20. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032) & (US$ Million) Figure 23. North America Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032) & (US$ Million) Figure 29. South America Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Human iPSCs
  • Mouse iPSCs
Applications
  • Academic Research
  • Drug Development and Discovery
  • Toxicity Screening
  • Regenerative Medicine
  • Others
Companies covered
  • Fujifilm Holding Corporation (CDI)
  • Ncardia
  • Sumitomo Dainippon Pharma
  • Astellas Pharma Inc
  • Fate Therapeutics, Inc
  • Pluricell Biotech
  • Cell Inspire Biotechnology
  • ReproCELL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Induced Pluripotent Stem Cells (iPSCs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Induced Pluripotent Stem Cells (iPSCs) Market Dynamics
  1. 2.1 Induced Pluripotent Stem Cells (iPSCs) Industry Trends
  2. 2.2 Induced Pluripotent Stem Cells (iPSCs) Industry Drivers
  3. 2.3 Induced Pluripotent Stem Cells (iPSCs) Industry Opportunities and Challenges
  4. 2.4 Induced Pluripotent Stem Cells (iPSCs) Industry Restraints
3 Induced Pluripotent Stem Cells (iPSCs) Market by Company
  1. 3.1 Global Induced Pluripotent Stem Cells (iPSCs) Company Revenue Ranking in 2025
  2. 3.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Company (2021-2026)
  3. 3.3 Global Induced Pluripotent Stem Cells (iPSCs) Company Ranking (2024-2026)
  4. 3.4 Global Induced Pluripotent Stem Cells (iPSCs) Company Manufacturing Base and Headquarters
  5. 3.5 Global Induced Pluripotent Stem Cells (iPSCs) Company Product Type and Application
  6. 3.6 Global Induced Pluripotent Stem Cells (iPSCs) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Induced Pluripotent Stem Cells (iPSCs) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Induced Pluripotent Stem Cells (iPSCs) Market by Type
  1. 4.1 Induced Pluripotent Stem Cells (iPSCs) Type Introduction
  2. 4.1.1 Human iPSCs
  3. 4.1.2 Mouse iPSCs
  4. 4.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type
  5. 4.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Type (2021-2032)
  7. 4.2.3 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type (2021-2032)
5 Induced Pluripotent Stem Cells (iPSCs) Market by Application
  1. 5.1 Induced Pluripotent Stem Cells (iPSCs) Application Introduction
  2. 5.1.1 Academic Research
  3. 5.1.2 Drug Development and Discovery
  4. 5.1.3 Toxicity Screening
  5. 5.1.4 Regenerative Medicine
  6. 5.1.5 Others
  7. 5.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application
  8. 5.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Application (2021-2032)
  10. 5.2.3 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application (2021-2032)
6 Induced Pluripotent Stem Cells (iPSCs) Regional Value Analysis
  1. 6.1 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032)
  7. 6.3.2 North America Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032)
  10. 6.4.2 Europe Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032)
  16. 6.6.2 South America Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Country, 2025 VS 2032
7 Induced Pluripotent Stem Cells (iPSCs) Country-level Value Analysis
  1. 7.1 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Induced Pluripotent Stem Cells (iPSCs) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Induced Pluripotent Stem Cells (iPSCs) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Induced Pluripotent Stem Cells (iPSCs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Fujifilm Holding Corporation (CDI)
  2. 8.1.1 Fujifilm Holding Corporation (CDI) Company Information
  3. 8.1.2 Fujifilm Holding Corporation (CDI) Business Overview
  4. 8.1.3 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  6. 8.1.5 Fujifilm Holding Corporation (CDI) Recent Developments
  7. 8.2 Ncardia
  8. 8.2.1 Ncardia Company Information
  9. 8.2.2 Ncardia Business Overview
  10. 8.2.3 Ncardia Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ncardia Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  12. 8.2.5 Ncardia Recent Developments
  13. 8.3 Sumitomo Dainippon Pharma
  14. 8.3.1 Sumitomo Dainippon Pharma Company Information
  15. 8.3.2 Sumitomo Dainippon Pharma Business Overview
  16. 8.3.3 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  18. 8.3.5 Sumitomo Dainippon Pharma Recent Developments
  19. 8.4 Astellas Pharma Inc
  20. 8.4.1 Astellas Pharma Inc Company Information
  21. 8.4.2 Astellas Pharma Inc Business Overview
  22. 8.4.3 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  24. 8.4.5 Astellas Pharma Inc Recent Developments
  25. 8.5 Fate Therapeutics, Inc
  26. 8.5.1 Fate Therapeutics, Inc Company Information
  27. 8.5.2 Fate Therapeutics, Inc Business Overview
  28. 8.5.3 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  30. 8.5.5 Fate Therapeutics, Inc Recent Developments
  31. 8.6 Pluricell Biotech
  32. 8.6.1 Pluricell Biotech Company Information
  33. 8.6.2 Pluricell Biotech Business Overview
  34. 8.6.3 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  36. 8.6.5 Pluricell Biotech Recent Developments
  37. 8.7 Cell Inspire Biotechnology
  38. 8.7.1 Cell Inspire Biotechnology Company Information
  39. 8.7.2 Cell Inspire Biotechnology Business Overview
  40. 8.7.3 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  42. 8.7.5 Cell Inspire Biotechnology Recent Developments
  43. 8.8 ReproCELL
  44. 8.8.1 ReproCELL Company Information
  45. 8.8.2 ReproCELL Business Overview
  46. 8.8.3 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  48. 8.8.5 ReproCELL Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst